Cannabis
Green Globe International, Inc. and Curated Nutra LLC Announce Joint Venture to Develop and Manufacture CBD, Nutritional Supplements, and Beauty Care Consumer Goods
GGII launches Green Star Labs, Inc., a 50/50 joint venture with a fifty-thousand square foot cGMP-certified laboratory and manufacturing facility in San Diego, CA
San Diego, California–(Newsfile Corp. – February 7, 2022) – Green Globe International Inc. (OTC Pink: GGII) (“GGII”) today announced it has entered into a joint venture agreement with Curated Nutra LLC to launch Green Star Labs, Inc. The new joint venture entity, owned 50% by each party, plans to develop CBD, nutritional supplements, and beauty care consumer goods. The new partnership comes with a staff of forty employees, an existing portfolio of clients, an R&D laboratory, a CBD testing lab, and manufacturing and packaging equipment for CBD, nutritional supplement, and beauty care products, including tinctures, capsules, soft gels, as well as topical CBD and beauty care consumer goods.
Highlights of Green Star Labs, Inc.:
- Cannabinoids Research & Development and Manufacturing
- Nutritional Supplement R&D and Manufacturing
- Beauty Care R&D and Manufacturing
- White Label and Private Label Partnerships in Beauty, Vitamins, and Cannabinoids
- Capacity to launch new brands in CBD, Vitamins, and Beauty
- Opportunity to place new brands into the company’s existing kiosk machines
- Ability to establish new CBD and vitamins product lines for convenience stores
- Boasts a cGMP, Organic and non-GMO certified (QAI), FDA certified, state of the art facility
“This joint venture comes with a highly experienced team, a cGMP-certified lab, manufacturing, and clients,” said Sandro Piancone, CEO of GGII. “We’re now looking for new partners to manufacture their beauty care, CBD, and nutraceutical products,” continued Mr. Sandro Piancone.
“We are very excited about this joint venture with GGII,” said Ryan Orear, CEO of Curated Nutra. “We are uniquely positioned to capture the established nutraceutical, skincare, and fast-growing CBD markets all under one roof. GGII brings incredible management, brand building, and product experience. Coupled with our manufacturing expertise and infrastructure, we are excited to build innovative products for our clients as well as our in-house brands,” continued Mr. Ryan Orear.
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7978/112965_ggii.h2.jpg
“We’re now a fully integrated development-to-retail Fast Moving Consumer Goods company,” said Jorge Olson, CMO of GGII. “We have an incredible team in Green Star Labs who is already working on our CBD and nutritional supplements brands,” concluded Mr. Jorge Olson.
Green Globe International is fulfilling its goal of bringing fast-moving consumer goods products, including nutritional supplements and beauty products, to market. According to a May 2021 Grand View Research report, the global nutritional supplements market was valued at USD 310.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2021 to 2028. According to Statista, the Beauty & Personal Care market is thriving and one of the fastest-growing consumer markets, driven in particular by the Cosmetics and Skin Care segments. Worldwide revenue in the Beauty & Personal Care market amounts to USD 564,438m in 2022. The market is expected to grow annually by 4.76% (CAGR 2022-2026).
Forward-Looking and Cautionary Statements
This news release may include forward-looking statements including opinions, assumptions, estimates, the Company’s assessment of future plans and operations, including but not limited to information concerning a potential combination with Hempacco and the timing thereof. When used in this document, the words “will,” “anticipate,” “believe,” “estimate,” “expect,” “intent,” “may,” “project,” “should,” and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded based on expectations and assumptions made by the Company. Forward-looking statements are subject to a wide range of risks and uncertainties. Although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to regulatory and third party approvals not being obtained in the manner or timing anticipated; the ability to implement corporate strategies; the state of domestic capital markets; the ability to obtain financing; changes in general market conditions; industry conditions and events; and other factors more fully described from time to time in the reports and filings made by the Company with OTC Markets Group, Inc. or the securities regulatory authorities. Except as required by applicable laws, the Company does not undertake any obligation to publicly update or revise forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of relevant securities laws and considered forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended.
# # #
About Green Globe International Inc. (GGII):
Green Globe and its subsidiaries develop, manufacture, market, and sell consumer goods, including herb and hemp smokables rolling paper. It trades on the OTC under the ticker GGII.
Green Globe and its subsidiaries current projects include:
- Herb and Cannabinoid Cigarettes, including CBD Cigarettes
- Manufacturing hemp rolling papers called hemp blunts
- 600 Vending Machines selling and advertising Consumer Goods
- Online sales of CBD products
- Joint Ventures with large distributors and celebrities like Rick Ross and Cheech & Chong
- The Real Stuff brand of hemp smokables
Add Your Name to the GGII Investor Email List
To be added to the GGII’s investor email list and be kept apprised of all upcoming IR activities, please subscribe using this link: https://newsroom.newsfilecorp.com/lists/8020/490
For more information, contact Sandro Piancone or Investor Relations at [email protected]
Investor Contact:
Dave Gentry, CEO
RedChip Companies
[email protected]
1-800-733-2447
Here are other Press Release headlines from GGII:
HempBox, a wholly-owned subsidiary of Green Globe International (GGII), enters into partnership with High Street CBD for a pilot program placing Vending Machines with premium quality CBD products in Tanger Outlets.
Cannabis Startup StickIt Signs a Joint Venture Agreement with Hempacco, a Green Globe International Division, to Produce 10 million CBD sticks per month
Green Globe and HBI Collaborate to Produce Hemp Wrap Smoking Rolling Paper Under the Skunk Name Brand
Hip-Hop Icon & Entrepreneur Rick Ross and Rap Snacks Founders and CEO, James Lindsay, Partner with Green
Globe - Hempacco to Launch Hemp Hop, a New Line of Hemp CBD Smokables, Delta 8, and Hemp Rolling Paper
Texas Opens to Smokable Hemp Along with a Potential $400 Million in Yearly Sales. What Does It Mean for GGII - Green Globe and Hemp CBD Cigarettes?
Green Globe Intl. - Hempacco Licenses Hemp Cigarette Manufacturing Technology to CBD Cigarette Company
Green Globe Intl. Signs LOI to Acquire Patent to Make Marijuana Paper
Green Globe Intl. – HempBox Vending Partners with Industry Giant SUZOHAPP to Rollout HempBoxes(TM) Across Its Network
Green Globe Intl. – Hempacco Partners with the Pelican Group to Rollout HempBoxesTM Nationwide
Green Globe Intl. – Hempacco Appoints Industry Veteran Dr. Stuart Titus as Chairman of The Board of Directors
GGII Announces 20 Billion Share Reduction in Issued and Outstanding Common Stock
GGII Green Globe – Hempacco Announces New Initiative to License Their Technology to Manufacture Cannabis Cigarettes
GGII Green Globe – Hempacco Receives Purchase Order for 250,000 packs of CBD Hemp Cigarettes from Ace & Axle, The Largest in Company History
GGII Green Globe – Hempacco launches CalivibesDelta8.com & Signs Joint Venture Agreement to launch Calivibes Delta8 Hemp Cigarettes with a 50% Ownership Stake
GGII Green Globe – Hempacco to Produce a Portfolio of Flavored Hemp Paper Wraps or Hemp Blunts, with the First Order of $230,000
GGII Green Globe – Hempacco Files Patent Application for Cigarette Filter Infusion Technology for Cannabis, Tobacco, Herb, and Hemp Cigarettes, Furthering Their Mission of Disrupting Tobacco
Green Globe – GGII Licenses Patent for Terpene Spraying Technology from Open Book Extracts, Furthering their Mission of Disrupting Tobacco
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112965
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
